About the Company
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $XLRN News
Acceleron Pharma
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates ...
Geron’s stock soars 95% after FDA advisory panel votes in favor of blood-disorder drug
Geron Corp.’s stock rose 95% Friday, after an advisory panel to the Food and Drug Administration voted 12-to-2 in favor of ...
Merck Agrees To Buy Rare Disease Specialist Acceleron Pharma For $11.5 Billon
Merck agreed to buy Acceleron Pharma Thursday in a deal that values the rare drug specialists at around $11.5 billion. Merck will pay $180 per share for Cambridge, Massachusetts-based Acceleron ...
Merck confirms $11.5bn Acceleron takeover deal
After days of speculation, Merck & Co confirmed today that it has agreed to acquire Acceleron Pharma $1.5 billion, setting up what could be one of the largest biopharma acquisitions of 2021 so far.
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
We are pleased to have Habib take on the role of Chair of the Board,” said Tim Noyes, Chief Executive Officer of Aerovate Therapeutics. “With the Phase 2b data readout from our global IMPAHCT trial of ...
Acceleron Corp Patents NudgeConvert Technology
Acceleron Bank Revolutionizes International Payments With NudgeConvert: Empowering Community Banks and Credit Unions To ...
BMS announces positive Reblozyl phase 3 results for MDS
Reblozyl is being developed and commercialised through a global collaboration with Merck, following Merck’s acquisition of Acceleron Pharma, Inc., in November 2021. Reblozyl is currently ...
Nuvectis Pharma, Inc. (NVCT)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Biopharma company to create 401 jobs in Wilson
The announcement came during a meeting of the state Department of Commerce’s Economic Investment Committee. The committee approves incentives packages for companies that commit to job creation in the ...
ORBIMED CAPITAL GP II LLC's Net Worth
This is based on reported shares across multiple companies, which include INSULET CORP, Volcano Corp, SUPERNUS PHARMACEUTICALS INC, AVANIR PHARMACEUTICALS, ACCELERON PHARMA INC, CRYOCOR INC ...
Topic - Acceleron Pharma
Acceleron Pharma, Inc. is a public American "clinical stage biopharmaceutical company" based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming ...
Geron's stock soars 95% after FDA advisory panel votes in favor of blood-disorder drug
Bristol-Myers Squibb (BMY) is developing Reblozyl via a collaboration with Merck & Co. Inc. (MRK) following Merck's takeover of Acceleron Pharma in late 2021. The company reported a 41% rise in ...
Loading the latest forecasts...